PMID- 27531722
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20240327
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 6
IP  - 8
DP  - 2016 Aug 16
TI  - Evidence for validity of a national physician and patient-reported, 
      cross-sectional survey in China and UK: the Disease Specific Programme.
PG  - e010352
LID - 10.1136/bmjopen-2015-010352 [doi]
LID - e010352
AB  - OBJECTIVE: Diabetes represents a significant challenge for Chinese healthcare 
      providers. Healthcare decision-making is generally based on many data sources, 
      including randomised controlled and real-world studies; however, good-quality 
      data from Chinese diabetes patients are scarce. We performed an initial 
      validation to assess the representativeness of one source of real-world data-the 
      Diabetes Adelphi Disease Specific Programme (DSP) in China. SETTING: China, UK. 
      PARTICIPANTS: The Chinese DSP included 2060 patients with previously diagnosed 
      type 2 diabetes mellitus (T2DM) sampled by 200 physicians. The reference Chinese 
      population comprised 238 639 patients with previously diagnosed T2DM. The UK DSP 
      contained 1481 patients with T2DM sampled by 125 physicians; the reference UK 
      population comprised 289 patients with diabetes. PRIMARY AND SECONDARY OUTCOMES: 
      The primary outcome was comparison of unweighted China DSP and reference data for 
      sex, body mass index (BMI), blood pressure (BP), patients achieving glycosylated 
      haemoglobin (HbA1c)<7%, total cholesterol, coronary heart disease and 
      dyslipidaemia. The secondary outcome was comparison of weighted UK DSP and 
      reference data for BMI, BP, mean HbA1c, total cholesterol, smoking and insulin 
      status. RESULTS: Comparison of unweighted China DSP and reference data revealed 
      statistical equivalence for BMI, systolic BP, proportion of patients achieving 
      HbA1c <7%, total cholesterol, coronary heart disease and dyslipidaemia. Sex, age, 
      diabetes duration, diastolic BP and mean HbA1c level were not equivalent, 
      although differences were generally small. Weighting of data did not 
      substantially affect the results. A similar pattern was observed for UK data. 
      CONCLUSIONS: This study provides evidence that the methodology used for the China 
      and UK parts of the Diabetes DSP produces representative samples that are 
      comparable with other independent sources of patient treatment outcomes data, 
      which may ultimately inform public health decision-making. Although this method 
      could be used in other countries, the current validation applies to UK and China. 
      Further research is required for other countries.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/
FAU - Babineaux, S M
AU  - Babineaux SM
AD  - Eli Lilly & Co, Indianapolis, Indiana, USA.
FAU - Curtis, B
AU  - Curtis B
AD  - Eli Lilly & Co, Indianapolis, Indiana, USA.
FAU - Holbrook, T
AU  - Holbrook T
AD  - Adelphi Real World, Macclesfield, UK.
FAU - Milligan, G
AU  - Milligan G
AD  - Adelphi Real World, Macclesfield, UK.
FAU - Piercy, J
AU  - Piercy J
AD  - Adelphi Real World, Macclesfield, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160816
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Pressure
MH  - Body Mass Index
MH  - China
MH  - Cholesterol/metabolism
MH  - Coronary Disease/epidemiology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology/metabolism
MH  - Dyslipidemias/epidemiology
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Patient Reported Outcome Measures
MH  - Physicians
MH  - Reproducibility of Results
MH  - Smoking/epidemiology
MH  - Surveys and Questionnaires
MH  - United Kingdom
PMC - PMC5013497
OTO - NOTNLM
OT  - China
OT  - Diabetes mellitus type 2
OT  - Survey Methodology
OT  - United Kingdom
OT  - Validation Study
EDAT- 2016/08/18 06:00
MHDA- 2017/12/06 06:00
PMCR- 2016/08/15
CRDT- 2016/08/18 06:00
PHST- 2016/08/18 06:00 [entrez]
PHST- 2016/08/18 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2016/08/15 00:00 [pmc-release]
AID - bmjopen-2015-010352 [pii]
AID - 10.1136/bmjopen-2015-010352 [doi]
PST - epublish
SO  - BMJ Open. 2016 Aug 16;6(8):e010352. doi: 10.1136/bmjopen-2015-010352.